United States securities and exchange commission logo





                            January 4, 2023

       Jun Yoon
       Chief Financial Officer
       Structure Therapeutics Inc.
       611 Gateway Blvd., Suite 223
       South San Francisco, CA 94080

                                                        Re: Structure
Therapeutics Inc.
                                                            Amendment No. 2 to
Draft Registration Statement on Form S-1
                                                            Submitted December
5, 2022
                                                            CIK No. 0001888886

       Dear Jun Yoon:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 2 to Draft Registration Statement on Form S-1

       Cover Page

   1.                                                   Disclose on your cover
page whether your offering is contingent upon final approval of
                                                        your NASDAQ listing
application. Please ensure the disclosure is consistent with your
                                                        underwriting agreement.
       Prospectus Summary, page 1

   2.                                                   Please disclose whether
you plan to conduct the Phase 2 trials for ANPA-0073 in the US
                                                        or in another country.
 Jun Yoon
FirstName  LastNameJun
Structure Therapeutics Inc.Yoon
Comapany
January    NameStructure Therapeutics Inc.
        4, 2023
January
Page 2 4, 2023 Page 2
FirstName LastName
Our Pipeline and Programs, page 4

3.       We note your use of the term    significant unmet medical needs
here and elsewhere in the
         document. Such a term might imply that your candidates are eligible
for fast track
         designation or priority review granted by the FDA for products that
treat certain serious
         unmet medical needs. Please remove your use of this term throughout or
otherwise please
         explain why you believe use of this term is appropriate.
Business, page 120

4.       Please revise the Business section, where appropriate, to present your
plans for
         the Phase 1b multiple ascending dose trial in GSBR-1290. In this
regard, we note your
         Summary disclosure indicates that in September 2022 you received FDA
allowance for
         the IND associated with this trial. Also discuss your current plans
for the Phase 2 trial
         for ANPA-0073.
Initial Public Offering Participation Rights, page 198

5.       We note your response to prior comment 3. Prior to effectiveness,
please revise the
         prospectus, where appropriate, to disclose whether the shares will be
offered as part of the
         public offering or in separate private placement.

Principal Shareholders, page 200

6.       Please revise to identify the natural person(s) with voting and/or
dispositive control over
         the shares held by ERVC Healthcare IV, L.P. and XX-I SHT Holdings
Limited.
        You may contact Vanessa Robertson at 202-551-3649 or Terence O'Brien at
202-551-
3355 if you have questions regarding comments on the financial statements and
related
matters. Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at
202-551-
6262 with any other questions.



                                                               Sincerely,

                                                               Division of
Corporation Finance
                                                               Office of Life
Sciences
cc:      Patrick Loofbourrow